Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
International Journal Of Molecular Sciences
Russo, Alessandro A; Franchina, Tindara T; Ricciardi, Giuseppina G; Battaglia, Alessandra A; Picciotto, Maria M; Adamo, Vincenzo V
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.
Therapeutic Advances In Medical Oncology
Elster, Naomi N; Toomey, Sinead S; Fan, Yue Y; Cremona, Mattia M; Morgan, Clare C; Weiner Gorzel, Karolina K; Bhreathnach, Una U; Milewska, Malgorzata M; Murphy, Madeline M; Madden, Stephen S; Naidoo, Jarushka J; Fay, Joanna J; Kay, Elaine E; Carr, Aoife A; Kennedy, Sean S; Furney, Simon S; Mezynski, Janusz J; Breathhnach, Oscar O; Morris, Patrick P; Grogan, Liam L; Hill, Arnold A; Kennedy, Susan S; Crown, John J; Gallagher, William W; Hennessy, Bryan B; Eustace, Alex A
Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.
Oncotarget
Deihimi, Safoora S; Lev, Avital A; Slifker, Michael M; Shagisultanova, Elena E; Xu, Qifang Q; Jung, Kyungsuk K; Vijayvergia, Namrata N; Ross, Eric A EA; Xiu, Joanne J; Swensen, Jeffrey J; Gatalica, Zoran Z; Andrake, Mark M; Dunbrack, Roland L RL; El-Deiry, Wafik S WS